Cornish businessman scoops Topra award
Jonathan Trethowan wins Inspiration category
A panel of five judges awarded Trethowan the honour at the awards, which recognise excellence within the industry, after he was nominated by Trac’s regulatory affairs executive, Lisa Pascoe.
Trethowan set up the company with his wife Sarah in 2001 and has seen it grow to work with UK and European pharmaceutical companies, ensuring that they are in compliance with the latest regulations concerned with the manufacture and marketing of medicines.
‘I am absolutely delighted to have won the Inspiration Award – it is a fantastic honour and to be honest I was thrilled just to be nominated,’ said Trethowan.
Pascoe added: ‘Over the past five years Jonathan has developed an excellent in-house training programme that has helped coach and support myself and six other graduates to become experienced regulatory professionals in our own right.
‘In addition, he also participates in a TOPRA working party that is identifying future approaches to professional development; I think his involvement at TRAC and within the industry as a whole shows his passion and commitment.’
You may also like
Regulatory
FDA rejects Summit Therapeutics’ ivonescimab lung cancer drug
The US regulator has issued a complete response letter for the PD-1/VEGF bispecific antibody, citing a lack of statistically significant overall survival benefit in a Phase III trial despite improvements in progression-free survival
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
Right-sized, not oversized: rethinking quality management technology for the UK's growing manufacturers (part II)
How the enterprise trap is set: familiar platforms, borrowed requirements and hidden validation costs can turn seemingly safe purchasing decisions into costly operational burdens
Regulatory
EU combination products: MDR, article 117 and drug-device approval risks
Bringing a drug-device combination product to market in Europe requires more than a strong pharmaceutical dossier and a functional delivery device. Companies must align two different development models, satisfy EU MDR expectations, manage notified-body involvement, and demonstrate that the drug and device work safely as one integrated product
Regulatory
Is your combination product really submission-ready?
A pharmaceutical team may consider a combination product nearly ready because the clinical, stability, quality, and drug data are in place. At the same time, the device team may still be completing design verification, usability studies, risk-management activities, or notified-body preparation
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.